Otros idiomas Pfizer Inc.

Acciones

PFE

US7170811035

Farmacéuticos

Mercado cerrado - Nyse Otros sitios de cotización 21:59:59 15/12/2025			Variación 5 días	Varia. 1 de enero.
26,45 ^USD	+2,32 %		+2,70 %	-0,25 %

20:09	La FDA aprueba fam-trastuzumab deruxtecan-nxki con pertuzumab	RE
19:51	Adaptive Biotechnologies anuncia dos acuerdos de licencia de receptores inmunitarios con Pfizer	CI

Otros idiomas

Fda approves fam-trastuzumab deruxtecan-nxki with pertuzumab	20:09
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer	19:51
Adaptive Biotechnologies signs two immune receptor licensing deals with Pfizer	15:31
Adaptive Biotechnologies Signs Target Discovery, Licensing Deals With Pfizer	15:09
Adaptive signs deal with Pfizer worth up to $890 million for rheumatoid arthritis research	14:56
TAGESVORSCHAU/Dienstag, 16. Dezember (vorläufige Fassung)	14:47
BGH prüft Hersteller-Haftung für Schäden nach Corona-Impfung	14:43
Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million	14:15
Wann Hersteller für etwaige Corona-Impfschäden haften müssen	07:36
US FDA approves Innoviva's oral antibiotic for gonorrhea	12/12
Pfizer Inc. Declares First-Quarter 2026 Dividend, Payable on March 6, 2026	12/12
Pfizer Declares First-Quarter 2026 Dividend	12/12
WOCHENVORSCHAU/15. bis 21. Dezember (51. KW)	12/12
Wall Street : Les baisses de taux ne vendent plus du rêve	12/12
Rate Cuts Can't Buy Confidence	12/12
Weight-loss drug developers line up to tap lucrative market as competition heats up	12/12
Health Rounds: Pfizer drug delays progression of advanced breast cancer in trial	12/12
US FDA Considering 'Black Box' Warning for COVID-19 Vaccines	12/12
Market Outlook: Injectable Drug Delivery Industry to Top US$1,034.78 Billion by 2030	12/12
GSK gets EU regulator backing for expanded use of RSV vaccine	12/12
US FDA expands use of GSK's Blujepa as treatment for gonorrhea	11/12
WHO weist US-Aussagen zu Impfstoffen und Autismus zurück	11/12
Sector Update: Health Care Stocks Mixed Premarket Thursday	11/12
Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth At 2025 Investor Day	11/12
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (Optimum-02) of Darovasertib in Combination with Crizotinib in First-Line HLA A2-Negative Metastatic Uveal Melanoma	11/12

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripciones Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Acciones

Novo y Pfizer aumentan sus ofertas por la startup Metsera en la batalla por la obesidad

04 de noviembre 2025 a las 19:28

Pfizer, Inc. : Bajo ataque total

08 de octubre 2024 a las 12:11